

## **Company Focus**

4 October 2007 | 12 pages

# **Reliance Petroleum (RPET.B0)**

# Re-Rating Nearing End? Downgrade to Hold

- All priced in, downgrade from Buy to Hold Our new target of Rs170 is a result of i) earnings upgrade (10-11% over FY10-12E) factoring in the potential savings from KG gas; ii) notwithstanding impact of rupee appreciation; iii) value of tax benefits (US\$2.8bn=Rs26/share); and iv) roll forward to Sep-08. Refining margin assumptions remain unchanged at US\$14.0-14.5/bbl.
- Premium to replacement cost justified but little room to improve RPL is trading at EV/bpd of US\$37,000 and EV per complexity bbl of US\$2,641, at premium to replacement costs - US\$25,000 and US\$2,000 respectively and RIL's imputed multiples. Even adjusting for the value of tax benefits (US\$2.8bn= US\$345 per complexity bbl) and benefits of Polypropylene unit, the current valuations do not leave much room for further re-rating.
- Cost savings from captive KG gas factored in We believe RPL could potentially gain from the differential between KG gas' delivered price (~US\$5.5/mmbtu) and likely pricing of refinery off-gases for the proposed ethylene cracker (at some discount to Naphtha prices). However, these assumptions are contingent on likely transfer pricing between RIL and RPL.
- Risks Stronger rupee and sharp decline in refining margins would be negative catalysts. Though there has been some debate on re-investment possibilities and its impact on value accretion and/or higher tax benefits, we believe it could be sometime away and partially factored into our valuations.

	Estimate change ☑
old/Low Risk	2L
from Buy/Low Risk	
ice (04 Oct 07)	Rs159.60
raat nrica	Rs170 00

Change in opinion 


✓ 

Target price change 

✓

Hold/Low Risk	2L
from Buy/Low Risk	
Price (04 Oct 07)	Rs159.60
Target price	Rs170.00
from Rs131.00	
Expected share price return	6.5%
Expected dividend yield	0.0%
Expected total return	6.5%
Market Cap	Rs718,200M
	US\$18,233M

#### Price Performance (RIC: RPET.BO. BB: RPET IN)



### Statistical Abstract

Year to	Net Profit	Diluted EPS	FPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2009E	53,859	12.0	na	13.4	3.9	29.4	0.7
2010E	89,604	19.9	66.4	8.0	2.8	40.4	1.7
2011E	97,638	21.7	9.0	7.4	2.1	32.7	2.5
2012E	95,268	21.2	-2.4	7.6	1.8	25.5	3.0
2013E	90,526	20.1	-5.0	7.9	1.5	20.4	2.8

Source: Powered by dataCentral

### Rahul Singh<sup>1</sup>

+91-22-6631-9863 rahul.r.singh@citi.com

### Saurabh Handa<sup>1</sup>

+91-22-6631-9858 saurabh.handa@citi.com

Garima Mishra<sup>1</sup> garima.mishra@citi.com

#### See Appendix A-1 for Analyst Certification and important disclosures.

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Customers of the Firm in the United States can receive independent third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at http://www.smithbarney.com (for retail clients) or http://www.citigroupgeo.com (for institutional clients) or can call (866) 836-9542 to request a copy of this research.

<sup>1</sup>Citigroup Global Markets India Private Limited

Valuation Ratios           PE adjusted (x)         13.4         8.0         7.4         7.6         7.9           EV/BBIDA adjusted (x)         13.9         7.2         6.2         5.7         5.3           P/BV (x)         3.9         2.8         2.1         1.8         1.5           Dividend yield (%)         0.7         1.9         2.7         3.3         3.1           Per Share Data (Rs)           EPS adjusted         11.97         19.91         21.70         21.17         20.12           EPS reported         11.97         19.91         21.70         21.17         20.12           BVPS         40.77         75.70         75.05         90.93         106.02           DPS         1.20         2.99         4.3         5.29         5.03           Profit & Loss (RsM)	Fiscal year end 31-Mar	2009E	2010E	2011E	2012E	2013E
EV/EBTIDA adjusted (x)         13.9         7.2         6.2         5.7         5.3           P/BV (x)         3.9         2.8         2.1         1.8         1.5           Druidend yield (%)         0.7         1.9         2.7         3.3         3.1           Per Share Data (Rs)         EPS adjusted         11.97         19.91         21.70         21.17         20.12           EPS adjusted         11.97         19.91         21.70         21.17         20.12           BVFS         40.77         57.70         75.05         90.93         106.02           DPS         1.20         2.99         4.34         5.29         5.03           Profit & Loss (RsM)           Net sales         310.697         546,004         57.47         5.09         3.8         562,437           Operating expenses         252.991         452,271         -47.51         -45668         -475,876           BEBT         57,06e         39.333         399.29         39.570         86.561           Bell iderest expense         3.887         9.62.21         -47.5668         -475.876           Fer tax profit         53.859         90.23         99.610         <	Valuation Ratios					
P/BV (c)   3.9   2.8   2.1   1.8   1.5	P/E adjusted (x)	13.4	8.0	7.4	7.6	7.9
Dividend yield (%)   0.7	=					
Fer Salquisted         11.97         19.91         21.70         21.17         20.12           EPS dijusted         11.97         19.91         21.70         21.17         20.12           EPS reported         11.97         19.91         21.70         21.17         20.12           BVPS         40.77         57.70         75.05         90.93         106.02           DPS         1.20         2.99         4.34         5.29         5.03           Profit & Loss (RsM)           Net sales         310.697         546.004         574.741         569.238         562.437           Operating expenses         -252.991         -452.271         -475.512         -475.668         -475.876           EBIT         57.06         93.733         99.293         93.570         665.61           Non-operating/exceptionals         0         1.837         5.5469         4.862         5.688           BRIT         0         6.19         1.972         -3.334         -4.965           EATraord./Min.Int./Pref.div.         0         6.619         9.1,972         -3.334         -4.965           EATraord./Min.Int./Pref.div.         0         6.19         1.972						
EPS adjusted         11.97         19.91         21.70         21.17         20.12           EPS reported         11.97         19.91         21.70         21.17         20.12           BVPS         40.77         57.70         75.05         90.93         10.602           DPS         1.20         2.99         4.34         5.29         5.03           Profit & Loss (RsM)           Net sales         310.697         546.004         574.741         569.238         562.437           Operating expenses         -252.991         -452.271         -475.512         -475.668         -475.868           EBIT         57.706         93.733         99.229         93.570         68.561           Net interest expense         -3,847         -5,347         -5,469         -4,862         -5,803           Non-operating/exceptionals         0         1,837         5,850         9,894         14,733           Pre-tax profit         53.899         90.223         99,610         98,602         95,811           Textraord./Min.Int./Pref.div.         0         0         0         0         0           Reported et income         53,859         89,604         97,638         95,268		0.7	1.9	2.7	3.3	3.1
EPS reported 11.97 19.91 21.70 21.17 20.12 BVPS 40.77 57.00 75.05 99.93 106.02 DPS 1.20 2.99 4.34 5.29 5.03 Profit & Loss (RSM)  Net sales 310.697 546.004 574.741 569.238 562.437 Operating expenses 252.991 452.271 475.512 475.668 475.876 EBIT 57,706 93.733 99.229 93.570 68.561 Net interest expense -3.847 -5.347 -5.469 4.862 -5.803 Non-operating/exceptionals 0 1.837 5.850 9.894 14.733 Pre-tax profit 53.859 90.223 99.10 98.602 55.491 Tax -6.99 1.992 39.570 68.561 Tax Pro-tax profit 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0						
BVPS         40.77         57.70         75.05         90.93         106.02           DPS         1.20         2.99         4.34         5.29         5.03           Profit & Loss (RsM)           Net sales         310.697         546,004         574,741         569,238         562,437           Operating expenses         -252,991         -452,271         -475,512         -475,668         -475,876           EBIT         57,706         93,733         99,229         93,570         86,561           Non-operating/exceptionals         0         1,837         5,850         9,834         14,733           Pre-tax profit         53,859         90,223         99,610         98,602         95,491           Tax         0         -619         -1,972         -3,334         -4,965           Adjusted dearnings         53,859         89,604         97,638         95,268         90,526           Adjusted EBITDA         57,706         107,383         113,034         107,531         100,733           Growth Rates (%)         Sales         na         75.7         5.3         -1.0         -1.2           BBIT adjusted         na         66.4         9.0         -2.4						
DPS         1.20         2.99         4.34         5.29         5.03           Profit & Loss (RsM)           Net sales         310.697         546,004         574,741         569,238         562,437           Operating expenses         -252,991         -452,271         -475,512         -475,668         475,876           BEBT         57,706         93,733         99,229         93,570         86,561           Net interest expense         -3,847         -5,347         -5,669         -4,862         -5,803           Non-operating/exceptionals         0         1,837         5,850         9,894         14,783           Tex profit         53,859         90,223         99,610         98,602         95,491           Tax         0         0         0         0         0         0           Extraord/Mini.Intr./Pref.div.         0         0         0         0         0         0           Extraord/Mini.Intr./Pref.div.         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0						
Profit & Loss (RSM)						
Net sales		1.20	2.99	4.34	5.29	5.03
Operating expenses         -252,991         -452,271         -475,512         -475,668         -475,876           EBIT         57,706         93,733         99,229         93,570         86,561           Net interest expense         -3,847         -5,347         -5,669         -4,862         -5,803           Non-operating/exceptionals         0         1,837         5,850         9,894         14,733           Pre-tax profit         53,859         90,223         99,610         98,602         95,491           Tax         0         -619         -1,972         -3,334         -4,965           Extraord/Min.Int./Pref.div.         0         0         0         0         0         0           Extraord/Min.Int./Pref.div.         0         0         0         0         0         0         0           Extraord/Min.Int./Pref.div.         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         2,268         90,526         0         0<	Profit & Loss (RsM)					
EBIT         57,706         93,733         99,229         93,570         86,561           Net interest expense         -3,847         -5,347         -5,469         -4,862         -5,803           Non-operating/exceptionals         0         1,837         5,850         9,894         14,733           Pre-tax profit         53,859         90,223         99,610         98,602         95,491           Tax         0         -619         -1,972         -3,334         -4,965           Extraord/Min.Int./Pref.div.         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0						
Net interest expense   -3,847   -5,347   -5,469   -4,862   -5,803   Non-operating/exceptionals   0   1,837   5,850   9,894   14,733   17ax   0   -619   -1,972   -3,334   -4,965   Extraord/Min.Int./Pref.div.   0   0   0   0   0   0   0   0   0						
Non-operating/exceptionals   0   1,837   5,850   9,894   14,733     Pre-tax profit   53,859   90,223   99,610   88,602   95,491     Tax						
Pre-tax profit         53,859         90,223         99,610         98,602         95,491           Tax         0         -619         -1,972         -3,334         -4,965           Extraord/Min.Int./Pref.div.         0         0         0         0           Reported net income         53,859         89,604         97,638         95,268         90,526           Adjusted EBITDA         57,706         107,383         113,034         107,531         100,730           Growth Rates (%)         Sales         na         75.7         5.3         -1.0         -1.2           EBIT adjusted         na         62.4         5.9         -5.7         -7.5           EBIT adjusted         na         86.1         5.3         -4.9         -6.3           EPS adjusted         na         86.1         5.3         -4.9         -6.3           EPS adjusted         na         66.4         9.0         -2.4         -5.0           Cash Flow (RsM)         0         13,650         13,866         13,962         14,170           Depreciating cash flow         53,859         70,240         107,767         106,347         100,289           Depreciation/amortization         0 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Tax         0         -619         -1,972         -3,334         -4,965           Extraord/Min.Int/Pref.div.         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         2.2.4         25.2         20.52         20.52         20.52         20.53         20.7         2.5.3         10.0         12.2         20.0         2.2.4         -5.0         2.5.7         -5.7         -5.7         -5.7         -5.7         -5.7         -5.3         -1.0         -1.2         2.0         2.0         2.4         -5.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0		-				,
Extraord / Min. Intr. / Pref. div.         0         0         0         0         0           Reported net income         53,859         89,604         97,638         95,268         90,526           Adjusted earnings         53,859         89,604         97,638         95,268         90,526           Adjusted EBITDA         57,706         107,383         113,034         107,531         100,730           Growth Rates (%)         Sales         na         75,7         5.3         -1.0         -1.2           EBIT adjusted         na         62,4         5.9         -5.7         -7.5           EBITDA adjusted         na         66.1         5.3         -4.9         -6.3           EPS adjusted         na         66.4         9.0         -2.4         -5.0           Cash Flow (RsM)           Operating cash flow         53,859         70,240         107,767         106,347         100,289           Depreciation/amortization         0         13,650         13,806         13,962         14,170           Net working capital         0         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td></th<>						
Reported net income         53,859         89,604         97,638         95,268         90,526           Adjusted earnings         53,859         89,604         97,638         95,268         90,526           Adjusted EBITDA         57,706         107,383         113,034         107,531         100,730           Growth Rates (%)         Sales         na         75,7         5.3         -1.0         -1.2           EBIT adjusted         na         62.4         5.9         -5.7         -7.5           EBITDA adjusted         na         66.4         9.0         -2.4         -5.0           EPS adjusted         na         66.4         9.0         -2.4         -5.0           Cash Flow (RsM)         0         -3.65         13,806         13,962         14,170           Net working cash flow         53,859         70,240         107,767         106,347         100,289           Depreciation/amortization         0         13,650         13,806         13,962         14,170           Net working cash flow         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -3,000         -4,00						
Adjusted earnings         53,859         89,604         97,638         95,268         90,526           Adjusted EBITDA         57,706         107,383         113,034         107,531         100,730           Growth Rates (%)         Sales         na         75.7         5.3         -1.0         -1.2           EBIT adjusted         na         66.4         5.9         -5.7         -7.5           EBIT DA adjusted         na         66.4         9.0         -2.4         -5.0           EPS adjusted         na         66.4         9.0         -2.4         -5.0           Cash Flow (RsM)           Operacing cash flow         53,859         70,240         107,767         106,347         100,289           Depreciation/amortization         0         13,650         13,806         13,962         14,170           Net working capital         0         -32,394         -1,705         452         559           Investing cash flow         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -6,				-	-	-
Adjusted EBITDA         57,706         107,383         113,034         107,531         100,730           Growth Rates (%)         Sales         na         75,7         5.3         -1.0         -1.2           EBIT adjusted         na         62.4         5.9         -5.7         -7.5           EBITDA adjusted         na         86.1         5.3         -4.9         -6.3           EPS adjusted         na         66.4         9.0         -2.4         -5.0           Cash Flow (RSM)         Upper caiting cash flow         53,859         70,240         107,767         106,347         100,289           Depreciation/amortization         0         13,650         13,806         13,962         14,170           Net working capital         0         -32,394         -1,705         452         559           Investing cash flow         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -30,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -30,000         -4,000           Capital expenditure         4,614         -19,67						
Growth Rates (%)         Sales         na         75.7         5.3         -1.0         -1.2           EBIT adjusted         na         62.4         5.9         -5.7         -7.5           EBITDA adjusted         na         86.1         5.3         -4.9         -6.3           EPS adjusted         na         66.4         9.0         -2.4         -5.0           Cash Flow (RsM)           Operating cash flow         53,859         70,240         107,767         106,347         100,289           Depreciation/amortization         0         13,650         13,806         13,962         14,170           Net working capital         0         -32,394         -1,705         452         559           Net working cash flow         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -3,000         -4,000           Acquisitions/disposals         0         0         0         0         0         0           Borrowings         36,141         4,614         -19,673         -31,993         17,621           Borrowings         36,141         10,000         <						
EBIT adjusted         na         62.4         5.9         -5.7         -7.5           EBITDA adjusted         na         86.1         5.3         -4.9         -6.3           EPS adjusted         na         66.4         9.0         -2.4         -5.0           Cash Flow (RSM)           Operating cash flow         53,859         70,240         107,767         106,347         100,289           Depreciation/amortization         0         13,650         13,806         13,962         14,170           Net working capital         0         -32,394         -1,705         452         559           Investing cash flow         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -3,000         -4,000           Acquisitions/disposals         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0						
EBIT adjusted na 62.4 5.9 -5.7 -7.5 EBITDA adjusted na 86.1 5.3 -4.9 -6.3 EPS adjusted na 66.4 9.0 -2.4 -5.0   Cash Flow (RsM)  Operating cash flow 53,859 70,240 107,767 106,347 100,289  Depreciation/amortization 0 13,650 13,806 13,962 14,170  Net working capital 0 -32,394 -1,705 452 559  Investing cash flow -90,000 -2,000 -3,000 -3,000 -4,000  Capital expenditure -90,000 -2,000 -3,000 -3,000 -4,000  Acquisitions/disposals 0 0 0 0 0 0 0 0 Financing cash flow 36,141 4,614 -19,673 -31,993 17,621  Borrowings 36,141 10,000 -6,233 -12,466 41,438  Dividends paid 0 -5,386 -13,441 -19,528 -23,817  Change in cash 0 72,855 85,094 71,354 113,910   Balance Sheet (RsM)  Total assets 266,119 395,455 475,005 538,279 646,426  Cash & cash equivalent 0 73,474 160,539 235,227 354,103  Accounts receivable 0 40,020 42,127 41,674 41,115  Net fixed assets 226,201 214,552 203,746 192,785 182,615  Total liabilities 82,646 135,819 137,258 129,081 169,334  Accounts payable 0 30,118 31,703 31,703 31,703  Total Debt 77,260 87,260 81,027 68,562 110,000  Shareholders' funds 183,473 259,636 337,747 409,198 477,092   Profitability/Solvency Ratios (%)  EITDA margin adjusted 18.6 19.7 19.7 18.9 17.9  ROE adjusted 29.4 40.4 32.7 25.5 20.4  ROIC adjusted 21.7 33.7 34.5 33.2 31.3  Net debt to equity 42.1 5.3 -23.5 -40.7 -51.2	Sales	na	75.7	5.3	-1.0	-1.2
EPS adjusted         na         66.4         9.0         -2.4         -5.0           Cash Flow (RsM)           Operating cash flow         53,859         70,240         107,767         106,347         100,289           Depreciation/amortization         0         13,650         13,806         13,962         14,170           Net working capital         0         -32,394         -1,705         452         559           Investing cash flow         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -3,000         -4,000           Acquisitions/disposals         0         0         0         0         0         0           Financing cash flow         36,141         4,614         -19,673         -31,993         17,621           Borrowings         36,141         10,000         -6,233         -12,466         41,438           Dividends paid         0         -5,386         -13,441         -19,528         -23,817           Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)           Total assets	EBIT adjusted	na			-5.7	-7.5
Cash Flow (RsM)         Operating cash flow         53,859         70,240         107,767         106,347         100,289           Depreciation/amortization         0         13,650         13,806         13,962         14,170           Net working capital         0         -32,394         -1,705         452         559           Investing cash flow         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -3,000         -4,000           Acquisitions/disposals         0         0         0         0         0         0           Financing cash flow         36,141         4,614         -19,673         -31,993         17,621           Borrowings         36,141         10,000         -6,233         -12,466         41,438           Dividends paid         0         -5,386         -13,441         -19,528         -23,817           Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)         10         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,12	EBITDA adjusted	na	86.1	5.3	-4.9	-6.3
Operating cash flow         53,859         70,240         107,767         106,347         100,289           Depreciation/amortization         0         13,650         13,806         13,962         14,170           Net working capital         0         -32,394         -1,705         452         559           Investing cash flow         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -3,000         -4,000           Acquisitions/disposals         0         0         0         0         0         0           Financing cash flow         36,141         4,614         -19,673         -31,993         17,621           Borrowings         36,141         10,000         -6,233         -12,466         41,438           Dividends paid         0         -5,386         -13,441         -19,528         -23,817           Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)         Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474	EPS adjusted	na	66.4	9.0	-2.4	-5.0
Depreciation/amortization   0   13,650   13,806   13,962   14,170   Net working capital   0   -32,394   -1,705   452   559   Investing cash flow   -90,000   -2,000   -3,000   -3,000   -4,000   Capital expenditure   -90,000   -2,000   -3,000   -3,000   -4,000   Acquisitions/disposals   0   0   0   0   0   0   0   0   0	Cash Flow (RsM)					
Net working capital Investing cash flow         0         -32,394         -1,705         452         559           Investing cash flow         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -3,000         -4,000           Acquisitions/disposals         0         0         0         0         0         0           Financing cash flow         36,141         4,614         -19,673         -31,993         17,621           Borrowings         36,141         10,000         -6,233         -12,466         41,438           Dividends paid         0         -5,386         -13,441         -19,528         -23,817           Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)           Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets	Operating cash flow	53,859	70,240	107,767	106,347	100,289
Investing cash flow         -90,000         -2,000         -3,000         -3,000         -4,000           Capital expenditure         -90,000         -2,000         -3,000         -3,000         -4,000           Acquisitions/disposals         0         0         0         0         0           Financing cash flow         36,141         4,614         -19,673         -31,993         17,621           Borrowings         36,141         10,000         -6,233         -12,466         41,438           Dividends paid         0         -5,386         -13,441         -19,528         -23,817           Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)           Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646		0		13,806	13,962	14,170
Capital expenditure         -90,000         -2,000         -3,000         -3,000         -4,000           Acquisitions/disposals         0         0         0         0         0         0           Financing cash flow         36,141         4,614         -19,673         -31,993         17,621           Borrowings         36,141         10,000         -6,233         -12,466         41,438           Dividends paid         0         -5,386         -13,441         -19,528         -23,817           Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)           Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable		-				
Acquisitions/disposals         0         0         0         0         0           Financing cash flow         36,141         4,614         -19,673         -31,993         17,621           Borrowings         36,141         10,000         -6,233         -12,466         41,438           Dividends paid         0         -5,386         -13,441         -19,528         -23,817           Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)           Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Financing cash flow         36,141         4,614         -19,673         -31,993         17,621           Borrowings         36,141         10,000         -6,233         -12,466         41,438           Dividends paid         0         -5,386         -13,441         -19,528         -23,817           Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)           Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473 <td></td> <td></td> <td></td> <td></td> <td>,</td> <td></td>					,	
Borrowings         36,141         10,000         -6,233         -12,466         41,438           Dividends paid         0         -5,386         -13,441         -19,528         -23,817           Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)         Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)						
Dividends paid         0         -5,386         -13,441         -19,528         -23,817           Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)           Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)           EBITDA margin adjusted         18.6         19.7         19.7         18.9	<del>-</del>					
Change in cash         0         72,855         85,094         71,354         113,910           Balance Sheet (RsM)         Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)           EBITDA margin adjusted         18.6         19.7         19.7         18.9         17.9           ROE adjusted         29.4         40.4         32.7         25.5         20.4           RO		,		,		
Balance Sheet (RsM)           Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)           EBITDA margin adjusted         18.6         19.7         19.7         18.9         17.9           ROE adjusted         29.4         40.4         32.7         25.5         20.4           ROIC adjusted         21.7         33.7         34.5         33.2         31.3						
Total assets         266,119         395,455         475,005         538,279         646,426           Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)           EBITDA margin adjusted         18.6         19.7         19.7         18.9         17.9           ROE adjusted         29.4         40.4         32.7         25.5         20.4           ROIC adjusted         21.7         33.7         34.5         33.2         31.3           Net debt to equity         42.1			,	,		
Cash & cash equivalent         0         73,474         160,539         235,227         354,103           Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)         EBITDA margin adjusted         18.6         19.7         19.7         18.9         17.9           ROE adjusted         29.4         40.4         32.7         25.5         20.4           ROIC adjusted         21.7         33.7         34.5         33.2         31.3           Net debt to equity         42.1         5.3         -23.5         -40.7         -51.2		266 110	305 455	475 005	538 270	646 426
Accounts receivable         0         40,020         42,127         41,674         41,115           Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)         EBITDA margin adjusted         18.6         19.7         19.7         18.9         17.9           ROE adjusted         29.4         40.4         32.7         25.5         20.4           ROIC adjusted         21.7         33.7         34.5         33.2         31.3           Net debt to equity         42.1         5.3         -23.5         -40.7         -51.2						
Net fixed assets         226,201         214,552         203,746         192,785         182,615           Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)           EBITDA margin adjusted         18.6         19.7         19.7         18.9         17.9           ROE adjusted         29.4         40.4         32.7         25.5         20.4           ROIC adjusted         21.7         33.7         34.5         33.2         31.3           Net debt to equity         42.1         5.3         -23.5         -40.7         -51.2						
Total liabilities         82,646         135,819         137,258         129,081         169,334           Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)           EBITDA margin adjusted         18.6         19.7         19.7         18.9         17.9           ROE adjusted         29.4         40.4         32.7         25.5         20.4           ROIC adjusted         21.7         33.7         34.5         33.2         31.3           Net debt to equity         42.1         5.3         -23.5         -40.7         -51.2						
Accounts payable         0         30,118         31,703         31,703         31,703           Total Debt         77,260         87,260         81,027         68,562         110,000           Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)           EBITDA margin adjusted         18.6         19.7         19.7         18.9         17.9           ROE adjusted         29.4         40.4         32.7         25.5         20.4           ROIC adjusted         21.7         33.7         34.5         33.2         31.3           Net debt to equity         42.1         5.3         -23.5         -40.7         -51.2						
Shareholders' funds         183,473         259,636         337,747         409,198         477,092           Profitability/Solvency Ratios (%)           EBITDA margin adjusted         18.6         19.7         19.7         18.9         17.9           ROE adjusted         29.4         40.4         32.7         25.5         20.4           ROIC adjusted         21.7         33.7         34.5         33.2         31.3           Net debt to equity         42.1         5.3         -23.5         -40.7         -51.2	Accounts payable	0		31,703		
Profitability/Solvency Ratios (%)           EBITDA margin adjusted         18.6         19.7         19.7         18.9         17.9           ROE adjusted         29.4         40.4         32.7         25.5         20.4           ROIC adjusted         21.7         33.7         34.5         33.2         31.3           Net debt to equity         42.1         5.3         -23.5         -40.7         -51.2						
EBITDA margin adjusted       18.6       19.7       19.7       18.9       17.9         ROE adjusted       29.4       40.4       32.7       25.5       20.4         ROIC adjusted       21.7       33.7       34.5       33.2       31.3         Net debt to equity       42.1       5.3       -23.5       -40.7       -51.2	Shareholders' funds	183,473	259,636	337,747	409,198	477,092
ROE adjusted       29.4       40.4       32.7       25.5       20.4         ROIC adjusted       21.7       33.7       34.5       33.2       31.3         Net debt to equity       42.1       5.3       -23.5       -40.7       -51.2	Profitability/Solvency Ratios (%)					
ROE adjusted       29.4       40.4       32.7       25.5       20.4         ROIC adjusted       21.7       33.7       34.5       33.2       31.3         Net debt to equity       42.1       5.3       -23.5       -40.7       -51.2	EBITDA margin adjusted	18.6	19.7	19.7	18.9	17.9
Net debt to equity 42.1 5.3 -23.5 -40.7 -51.2						
Total debt to capital         29.6         25.2         19.3         14.4         18.7						
	lotal debt to capital	29.6	25.2	19.3	14.4	18.7

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



# Earnings upgraded, factoring in cost savings

RPL proposes to use KG gas for captive power/steam generation and other utilities.

- 1. We have assumed 50% of the Fuel & Loss (8%) to comprise refinery offgases which can be replaced by natural gas for generating power and steam for the refinery.
- 2. While delivered price of KG gas is likely to be ~US\$5.5/mmbtu (it could be higher also), RPL is likely to get higher realization for its refinery off-gases which will be benchmarked to Naphtha (US\$16/mmbtu). This will provide additional revenues for RPL. We have assumed mid-point of prevailing natural gas price and Naphtha to estimate the likely revenue accretion.
- 3. Please note that the above assumptions are subject to the transfer pricing arrangement between RIL and RPL for natural gas as well as refinery offgases.
- 4. Also, RPL's power and steam requirements will be met by an affiliate company, Reliance Utilities and Power Ltd. (RUPL), which presumably would be the main consumer of natural gas for converting to power/steam. Our calculations assume RUPL operates on a cost-plus basis (like all utilities) with the variable fuel cost being a pass-through.

So while our refining margin assumptions remain unchanged at US\$14.0-14.5/bbl over FY2009-11E, our earnings upgrade is primarily a result of the savings from KG gas notwithstanding stronger rupee assumptions.

Year to	Net Prof	fit (Rs Mils.)		Diluted EPS (	Rs)	Divi. Pe	r Share (Rs)
31-Mar	Old	New	Old	New	% Chg	Old	New
2009E	49,486	53,859	11.00	11.97	8.8%	1.1	1.2
2010E	81,148	89,604	18.03	19.91	10.4%	2.7	3.0
2011E	88,500	97,638	19.67	21.70	10.3%	3.9	4.3
2012E	85,889	95,268	19.09	21.17	10.9%	4.8	5.3

Figure 2. Refining Margin Assumptions



Source: Citi Investment Research estimates

# Valuation target upped to Rs170

Our target price (rolled forward to Sep-08) is based on:

Core value at 12-month forward EV/EBITDA of 7.0x (in line with peers) as on Sep-08. We estimate 12-mnth fwd EBITDA as sum of 2HFY09E and 1HFY10E.

+

Present value of tax benefits as on Sep-08 = US\$2.8bn = Rs26/share

Figure 3. Valuation framework					
EV/EBITDA (x)	6.0x	6.5x	7.0x	7.5x	8.0x
EBITDA - 12m fwd as on Sep'08 - Rs m	111,398	111,398	111,398	111,398	111,398
EV (as on Sep-08) - US\$bn	16.7	18.1	19.5	20.9	22.3
Debt (as on Sep-08) - US\$bn	3.3	3.3	3.3	3.3	3.3
Equity value (as on Sep-08) - US\$bn	13.4	14.8	16.2	17.6	19.0
Value per share	119	132	144	157	169
Value of tax benefits			26		
Target price (Rs)			170		
Source: Citi Investment Research estimates	1				

# Asset valuations leave little room to improve

RPL is trading at EV/complexity bbl of US\$2,641/complexity bbl, significant premium to prevailing replacement costs of US\$2,000-2,200/complexity bbl. Though a part of this premium (US\$345/complexity bbl to be precise) can be attributed to the NPV of tax benefits (US\$2.8bn), the valuations are rich even after adjusting for that. Notwithstanding the current tightness in the EPC

market and the soaring costs, we believe RPL's valuations are at the higher end of replacement costs and leave little room for further re-rating. Recently announced expansion of Shell's Port Arthur Refinery (Texas, US) at US\$21,500 is also reflective of the current replacement costs.

This is also borne out of the peer comparison (see Figure 4 below); infact RPL is trading at significant premium to even its more established parent (RIL's) imputed EV/bpd. Please note that RIL's refinery also enjoys material tax benefits and is therefore a closer comparable to RPL.

Figure 4.	Asset V	/aluation	Compara	ıbles
-----------	---------	-----------	---------	-------

	RIC Code	EV (US\$m)	Throughput (kbpd)	Nelson's Complexity	EV/ bbl (US\$)	EV/ complexity bbl (US\$)
RPL (at CMP)	RPET.B0	21,445	580	14.0	36,974	2,641
RPL (at target)	RPET.B0	22,425	580	14.0	38,664	2,762
RIL (EV/E of 6.5X)	RELI.BO	16,262	660	11.3	24,639	2,180
Chennai Petroleum	CHPC.B0	1,688	210	8.0	8,039	1,005
Thai Oil	TOP.BK	3,724	241	8.4	15,453	1,844
Mangalore Refinery	MRPL.B0	3,734	250	9.0	14,936	1,660
Bongaigaon Refinery	BNGR.B0	366	48	6.0	7,622	1,270
SUN.N	Sunoco	8,741	900	8.5	9,713	1,143
TSO.N	Tesoro	6,545	658	9.5	9,946	1,047
VLO.N	Valero	41,036	3260	11.2	12,588	1,124

Source: Citi Investment Research estimates

 ${\bf Figure~5.~Global~Refining-Valuation~Comparables}$ 

			Mkt Cap	Price	Target	P	/E (x)	EV/EI	BITDA (x)	P/	BV (x)	Div.	Yield (%)	R0	CE (%)
Company Name	RIC Code	Rating	(US\$m)	2-0ct-07	price	FY08E	FY09E	FY08E	FY09E	FY08E	FY09E	FY08E	FY09E	FY08E	FY09E
Asia			(004)		<b>J</b>										
CPCL	CHPC.B0	1L	1,078	287	360	6.2	7.5	4.9	5.2	1.4	1.2	5.7%	4.7%	13.7%	11.5%
															21.2%
PTT	PTT.BK	1L	29,463	332	349	11.1	10.1	7.7	6.8	2.7	2.3	3.8%	3.8%	20.7%	
Thai Oil	TOP.BK	1M	5,663	88	94	11.4	9.6	10.6	9.1	2.0	1.8	5.9%	5.4%	13.9%	16.59
Sinopec	0386.HK	3L	21,619	10	8	13.2	12.1	2.5	2.5	2.8	2.3	1.8%	2.0%	14.6%	14.19
S Sh Pechem	0338.HK	2M	1,912	6	6	18.9	19.4	4.8	4.1	2.2	2.0	2.0%	2.0%	8.1%	10.0%
Formosa Petro	6505.TW	2L	28,525	101	85	14.9	14.7	11.3	10.4	3.9	3.8	6.2%	6.2%	18.0%	18.39
Asia Avg.			,			13.0	12.2	7.7	7.0	3.0	2.8	4.2%	4.2%	17.5%	17.9%
Cosmo Oil Co Ltd	5007.T	3H	3,103	535	540	13.4	18.0	7.1	7.8	1.0	1.0	1.5%	1.5%	4.2%	3.3%
Nippon Oil	5001.T	3H	13,630	1,079	1,110	21.0	27.2	7.2	7.7	1.2	1.2	1.1%	1.1%	3.2%	2.7%
Npn Min Holdings	5016.T	1 M	9,180	1,146	1,500	10.6	10.6	10.5	11.9	1.5	1.3	1.4%	1.4%	9.6%	9.4%
AOC Holdings	5017.T	1H	1,226	1,837	2,760	7.5	17.3	7.0	10.0	1.0	1.0	0.8%	0.8%	8.6%	4.0%
TonenGeneral	5012.T	2M	5,865	1,164	1,340	17.1	15.9	9.2	9.6	3.0	3.4	3.4%	3.7%	9.9%	10.29
Showa Shell	5002.T	3M	4,863	1,494	1,160	14.8	20.1	8.0	9.4	1.5	1.4	2.4%	2.4%	6.3%	4.6%
Japan Avg.			.,	-,	-,	16.0	19.4	8.4	9.3	1.6	1.6	1.7%	1.8%	6.4%	5.8%
US															
Valero	VLO.N	2H	37,605	68	68	7.3	8.9	4.2	5.4	2.2	1.9	0.7%	0.7%	20.3%	14.6%
Tesoro	TSO.N	2H	6,485	47	51	7.7	7.0	3.6	4.0	1.9	1.5	0.7%	0.8%	20.5%	17.59
Delek US HIdg	DK.N	2S	1,307	25	27	9.2	13.8	5.5	6.9	2.5	2.2	1.4%	0.6%	26.4%	16.09
Sunoco	SUN.N	2H	8,560	71	75	8.2	8.3	4.5	4.9	3.1	2.5	1.5%	1.5%	18.8%	14.89
US Avg.						7.6	8.7	4.2	5.2	2.3	2.0	0.9%	0.9%	20.2%	15.0%
Canada															
Imperial Oil Ltd	IMO.TO	2M	44,386	48	53	15.4	16.0	8.1	7.8	5.5	4.2	0.7%	0.8%	29.5%	26.39
Petro-Canada	PCA.TO	2M	27,192	56	60	10.6	11.1	3.6	4.0	2.3	1.9	0.9%	0.9%	23.5%	19.89
	SU.TO			92		18.4				3.8	3.1	0.4%	0.5%	13.5%	12.79
Suncor Energy	50.10	1M	42,663	92	116		16.0	10.6	9.6						
Canada Avg.						15.4	14.8	8.0	7.6	4.1	3.2	0.7%	0.7%	22.1%	19.7%
Europe															
ERG	ERG.MI	2H	3,242	15	18	15.0	7.9	6.1	4.9	1.6	1.4	1.3%	3.2%	7.6%	10.09
Hellenic Petroleum	HEPr.AT	2H	4,862	11	11	13.3	13.1	9.1	8.3	1.4	1.3	3.8%	3.8%	7.9%	8.0%
MOL	MOLB.BU	3H	17,334	28,110	24,000	14.0	14.4	7.4	9.3	5.4	4.1	1.9%	2.1%	16.9%	15.69
Motor Oil	MORr.AT	1M	2,901	19	26	10.6	10.5	8.1	8.2	4.8	4.6	9.0%	9.1%	19.7%	18.99
Neste Oil	NES1V.HE		9,185	25	28	11.5	10.5	7.7	7.0	2.7	2.4	4.3%	4.8%	16.8%	15.89
		1L													
OMV Europe Avg.	OMVV.VI	2H	20,635	49	54	9.6 <b>11.9</b>	9.0 <b>11.2</b>	5.1 <b>6.7</b>	4.8 <b>7.0</b>	1.8 <b>3.1</b>	1.6 <b>2.6</b>	2.3% <b>2.9%</b>	3.2% <b>3.4%</b>	14.4% <b>14.9%</b>	14.9% <b>14.6</b> %
EMEA															
Sasol	SOLJ.J	1M	28,873	318	350	12.7	10.3	7.2	6.7	3.2	2.6	2.8%	3.3%	19.2%	18.39
PKN ORLEN	PKNA.WA	2M	9,161	57	62	10.7	8.2	6.1	5.3	1.1	1.1	2.8%	3.7%	9.1%	10.29
Tupras	TUPRS.IS	2M	6,517	32	19	12.8	12.8	9.7	8.8	2.8	2.7	6.3%	6.3%	19.8%	21.29
Petrol Ofisi AS	PTOFS.IS	2H	2,540	6	6	68.3	12.5	6.5	7.4	1.8	1.6	0.0%	0.0%	16.4%	12.39
Gazpromneft															
•	SIBN.RTS	2M	20,245	4	4	6.9	8.0	4.9	5.2	1.7	1.4	3.0%	2.6%	27.4%	22.09
Surgutneftegaz	SNGS.RTS	3H	48,945	1	1	13.9	15.5	5.6	5.9	2.0	1.9	1.6%	1.4%	21.4%	16.79
Tatneft	TATN.RTS	3H	12,092	6	5	10.7	12.0	8.0	9.1	1.3	1.3	3.2%	2.5%	10.5%	8.8%
Lukoil	LKOH.RTS	2L	71,958	85	78	9.6	10.5	6.7	7.0	1.8	1.6	2.6%	2.4%	17.6%	14.39
TNK-BP Holding	TNBPI.RTS	18	32,488	2	2	7.1	8.3	4.2	4.7	3.3	2.8	7.0%	6.0%	29.4%	22.99
EMEA Avg.			52,100	-	-	11.1	11.1	6.1	6.3	2.2	1.9	3.2%	3.0%	20.4%	16.99
Total Avg.						12.3	12.3	6.8	6.8	2.7	2.3	2.5%	2.5%	18.8%	16.59
i viui nig.						12.0	12.0	0.0	0.0	4.7	2.0	2.0/0	2.0/0	. 0.0 /0	

# **Reliance Petroleum**

## Company description

RPL is presently 75% owned by Reliance Industries (RIL) and is setting up a super-size greenfield refinery (580,000bpd) and polypropylene plant in Jamnagar in the State of Gujarat. The project cost is estimated at Rs270bn (US\$6bn), of which 50% has been raised as equity through the promoter contribution and Initial Public Offering in early FY07. The project is scheduled to commission in mid-2008.

### Investment strategy

We rate Reliance Petroleum (RPL) Hold/Low Risk (2L) rating with a target price of Rs170. RPL is constructing a super-sized refinery (580kbpd) targeted at export markets. Key competitive advantages that we expect to aid sustenance of superior margins include a heavier crude mix, product flexibility, and superior fuel specs. A tried-and-tested location and parent RIL's strong execution track record imparts RPL a head start over competing projects, which are getting delayed. RPL's proposed refinery would operate as swing capacity catering to product-specific demand across refining basins. We expect tightening fuel specs, especially in the US and Europe, will continue to drive demand for high-quality, differentiated products. However, the stock has undergone a sharp re-rating over the last 6 months on the back of favorable global environment, rising replacement costs and demonstrated strong execution leaving moderate upside potential.

#### **Valuation**

Our valuation methodology uses a traditional EV/EBITDA multiple as on September-08 applied on 12-mnth forward EBITDA i.e. 2HFY09E plus 1HFY10E. In addition, we value the tax benefits separately which is added to the core value to arrive at the target price. We believe EV/EBITDA is an appropriate valuation metric as it eliminates variations due to capital structure and taxation, thus facilitating peer comparison.

We believe that RPL, with its level of complexity (which we believe accords sustainability to margins) continues to warrant a valuation at the higher end of peers i.e., a 12-month forward EV/EBITDA of 7.0x (earlier 6.5x). Based on our GRM assumptions and the highly remunerative tax regime, we value the tax benefits to be worth NPV of US\$2.8bn (Rs26/share). This together with core value based on 12-mnth fwd EBITDA multiple (Rs144/share) is the basis of our new target of Rs170/share.

#### Risks

Our quantitative risk rating system suggests a Low Risk rating to RPL. We believe that RPL's strong parentage and remarkable project progress mitigate the execution risks to a large extent and lend support to the Low Risk rating. Favorable demand-supply economics in refining and RPL's positioning to take advantage from the situation provide further comfort.

Any of the following risk factors could result in downside risk to our target price: 1) Sharp decline in refining margins due to demand slowdown and/or quicker-than-expected commissioning of greenfield capacities globally; 2) Decline in L/H crude differential; and 3) Continued rupee appreciation. In the long term, any move to merge with the parent, RIL, could pose risks to the stock although Chevron's present stake of 5% (and option to acquire further 24%) would act as impediments.


Any of the following risk factors could result in upside to our target price: 1) Further strengthening of refining margins; 2) Re-investment of free cash flows in capacity additions which could be value accretive in addition to sustaining the tax breaks beyond the first 10 years; and 3) Higher than anticipated cost savings from the KG basin gas.

# **Appendix A-1**

## **Analyst Certification**

Each research analyst(s), strategist(s) or research associate(s) responsible for the preparation and content of this research report hereby certifies that, with respect to each issuer or security that the research analyst, strategist or research associate covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) strategist(s) or research associate(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst, strategist or research associate in this research report.

### IMPORTANT DISCLOSURES



Customers of the Firm in the United States can receive independent third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at http://www.smithbarney.com (for retail clients) or http://www.citigroupgeo.com (for institutional clients) or can call (866) 836-9542 to request a copy of this research.

A director of Reliance Industries serves as a director on Citigroup's International Advisory Board.

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Chennai Petroleum, ERG, Lukoil Holdings and Reliance Industries. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Lukoil Holdings, Showa Shell Sekiyu, Suncor Energy Inc, Sunoco, Inc and Valero Energy Corp.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Chevron Corp, Delek US HIdg Inc, ERG, Formosa Petrochemical, Gazpromneft, Imperial Oil Ltd, Lukoil Holdings, Mangalore Refinery & Petr, Motor Oil, Neste Oil, Nippon Mining Holdings, Nippon Oil, OMV, Petro-Canada, PKN Orlen SA, PTT, Reliance Industries, Reliance Petroleum, Showa Shell Sekiyu, Sinopec, Sinopec Shanghai Petrochemical, Suncor Energy Inc, Sunoco, Inc, Thai Oil, TNK-BP Holding, TonenGeneral Sekiyu, TUPRAS and Valero Energy Corp.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from Chevron Corp, Gazpromneft, Lukoil Holdings, Mangalore Refinery & Petr, Neste Oil and Sinopec.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Chennai Petroleum, Chevron Corp, Cosmo Oil, Delek US Hldg Inc, ERG, Formosa Petrochemical, Gazpromneft, Hellenic Petroleum, Imperial Oil Ltd, Lukoil Holdings, Mangalore Refinery & Petr, MOL, Motor Oil, Neste Oil, Nippon Mining Holdings, Nippon Oil, OMV, Petro-Canada, Petrol Ofisi, PKN Orlen SA, PTT, Reliance Industries, Sasol, Showa Shell Sekiyu, Sinopec, Sinopec Shanghai Petrochemical, Suncor Energy Inc, Sunoco, Inc, Surgutneftegas, Tatneft, Tesoro Corp., Thai Oil, TNK-BP Holding, TonenGeneral Sekiyu, TUPRAS and Valero Energy Corp in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): Chevron Corp, Delek US HIdg Inc, ERG, Formosa Petrochemical, Gazpromneft, Imperial Oil Ltd, Lukoil Holdings, Mangalore Refinery & Petr, Motor Oil, Neste Oil, Nippon Mining Holdings, Nippon Oil, OMV, Petro-Canada, PKN Orlen SA, PTT, Reliance Industries, Reliance Petroleum, Showa Shell Sekiyu, Sinopec, Sinopec Shanghai Petrochemical, Suncor Energy Inc, Sunoco, Inc, Thai Oil, TNK-BP Holding, TonenGeneral Sekiyu, TUPRAS and Valero Energy Corp.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Chevron Corp, Cosmo Oil, Delek US Hldg Inc, ERG, Formosa Petrochemical, Gazpromneft, Hellenic Petroleum, Imperial Oil Ltd, Lukoil Holdings, Mangalore Refinery & Petr, MOL, Motor Oil, Neste Oil, Nippon Mining Holdings, Nippon Oil, OMV, Petro-Canada, Petrol Ofisi, PKN Orlen SA, PTT, Reliance Industries, Sasol, Showa Shell Sekiyu, Sinopec, Sinopec Shanghai Petrochemical, Suncor Energy Inc, Sunoco, Inc, Surgutneftegas, Thai Oil, TNK-BP Holding, TonenGeneral Sekiyu, TUPRAS and Valero Energy Corp.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Chennai Petroleum, Chevron Corp, Cosmo Oil, Delek US Hldg Inc, ERG, Formosa Petrochemical, Gazpromneft, Hellenic Petroleum, Imperial Oil Ltd, Lukoil Holdings, Mangalore Refinery & Petr, MOL, Motor Oil, Neste Oil, Nippon Oil, OMV, Petro-Canada, Petrol Ofisi, PKN Orlen SA, PTT, Reliance Industries, Sasol, Showa Shell Sekiyu, Sinopec, Sinopec Shanghai Petrochemical, Suncor Energy Inc, Sunoco, Inc, Surgutneftegas, Tatneft, Tesoro Corp., Thai Oil, TNK-BP Holding, TonenGeneral Sekiyu, TUPRAS and Valero Energy Corp.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

The Firm is a market maker in the publicly traded equity securities of Chevron Corp, Imperial Oil Ltd, Lukoil Holdings, Petro-Canada, Sasol, Sinopec, Suncor Energy Inc, Sunoco, Inc, Surgutneftegas, Tesoro Corp. and Valero Energy Corp.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

## Citi Investment Research Ratings Distribution

Data current as of 30 September 2007	Buy	Hold	Sell
Citi Investment Research Global Fundamental Coverage (3358)	50%	38%	12%
% of companies in each rating category that are investment banking clients	53%	55%	42%

#### **Guide to Fundamental Research Investment Ratings:**

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating

For securities in developed markets (US, UK, Europe, Japan, and Australia/New Zealand), investment ratings are: Buy (1) (expected total return of 10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks); Hold (2) (0%-10% for Low-Risk stocks, 0%-15% for Medium-Risk stocks, 0%-20% for High-Risk stocks, and 0%-35% for Speculative stocks); and Sell (3) (negative total return).

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings:

Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at http://sd.ny.ssmb.com/ using the "Indexes" tab; Hold/Neutral Weight the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underper

### OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 03 October 2007 04:15 PM on the issuer's primary market.

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to Chevron Corp, Cosmo Oil, Gazpromneft, Lukoil Holdings, Neste Oil, Nippon Oil, OMV, Petro-Canada, Reliance Industries, Sinopec, Suncor Energy Inc, Suncoo, Inc and TNK-BP Holding. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citigroupgeo.com.)

Citigroup Global Markets Inc. or its affiliates beneficially owns 2% or more of any class of common equity securities of Chennai Petroleum and Lukoil Holdings.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the

Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi Smith Barney Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11° andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl., Jend. Sudirman Kay. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 5574-4860 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore.

### Reliance Petroleum (RPET.BO)

4 October 2007

1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5. Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

This Product is not intended for distribution in Poland. Any receipt or review of the Product in Poland is not authorized by the Firm.

© 2007 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service marks of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST